Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Theravance Biopharma, Inc. (TBPH) had Stock-Based Compensation of $14.00M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$19.99M |
|
$3.62M |
|
-- |
|
$19.99M |
|
$26.45M |
|
$-6.46M |
|
$3.57M |
|
$-2.89M |
|
$-2.89M |
|
$3.62M |
|
$3.62M |
|
$3.62M |
|
$3.62M |
|
$-6.46M |
|
$-6.82M |
|
50.52M |
|
51.91M |
|
$0.07 |
|
$0.07 |
|
| Balance Sheet Financials | |
$354.70M |
|
$6.26M |
|
$60.76M |
|
$415.46M |
|
$37.41M |
|
-- |
|
$145.37M |
|
$182.78M |
|
$232.68M |
|
$232.68M |
|
$232.68M |
|
50.67M |
|
| Cash Flow Statement Financials | |
$244.60M |
|
$-105.87M |
|
$-1.76M |
|
$38.63M |
|
$175.61M |
|
$136.98M |
|
|
Stock-Based Compensation |
$14.00M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.48 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-32.29% |
|
-32.29% |
|
-- |
|
-14.45% |
|
18.08% |
|
$244.57M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
1.09 |
|
82.24 |
|
1.55% |
|
1.55% |
|
0.87% |
|
1.55% |
|
$4.59 |
|
$4.71 |
|
$4.71 |
|